CY1108223T1 - Αντιγονα στρεπτοκοκκου - Google Patents

Αντιγονα στρεπτοκοκκου

Info

Publication number
CY1108223T1
CY1108223T1 CY20081100787T CY081100787T CY1108223T1 CY 1108223 T1 CY1108223 T1 CY 1108223T1 CY 20081100787 T CY20081100787 T CY 20081100787T CY 081100787 T CY081100787 T CY 081100787T CY 1108223 T1 CY1108223 T1 CY 1108223T1
Authority
CY
Cyprus
Prior art keywords
streptococcal
disclosed
proteins
streptococcal antigens
streptococcal infection
Prior art date
Application number
CY20081100787T
Other languages
Greek (el)
English (en)
Inventor
Josée Hamel
Bernard R Brodeur
Isabelle Pineau
Denis Martin
Clement Rioux
Nathalie Charland
Original Assignee
Id Biomedical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108223(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Id Biomedical Corporation filed Critical Id Biomedical Corporation
Publication of CY1108223T1 publication Critical patent/CY1108223T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CY20081100787T 1998-12-23 2008-07-29 Αντιγονα στρεπτοκοκκου CY1108223T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23
EP99960748A EP1141306B1 (en) 1998-12-23 1999-12-20 Streptococcus antigens

Publications (1)

Publication Number Publication Date
CY1108223T1 true CY1108223T1 (el) 2014-02-12

Family

ID=22351610

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20081100787T CY1108223T1 (el) 1998-12-23 2008-07-29 Αντιγονα στρεπτοκοκκου
CY20121101268T CY1114722T1 (el) 1998-12-23 2012-12-27 Αντιγονα στρεπτοκοκκου
CY20141100536T CY1115340T1 (el) 1998-12-23 2014-07-16 Νεο αντιγονο στρεπτοκοκκου

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20121101268T CY1114722T1 (el) 1998-12-23 2012-12-27 Αντιγονα στρεπτοκοκκου
CY20141100536T CY1115340T1 (el) 1998-12-23 2014-07-16 Νεο αντιγονο στρεπτοκοκκου

Country Status (29)

Country Link
EP (2) EP1141306B1 (enExample)
JP (2) JP4761623B2 (enExample)
KR (4) KR100891398B1 (enExample)
CN (3) CN101134775A (enExample)
AP (1) AP2001002199A0 (enExample)
AR (1) AR029322A1 (enExample)
AT (1) ATE394489T1 (enExample)
AU (1) AU1764900A (enExample)
BR (1) BR9916477A (enExample)
CA (1) CA2356836C (enExample)
CL (1) CL2009002037A1 (enExample)
CY (3) CY1108223T1 (enExample)
CZ (2) CZ302790B6 (enExample)
DE (1) DE69938670D1 (enExample)
DK (3) DK1141306T3 (enExample)
EA (1) EA007409B1 (enExample)
ES (3) ES2306528T3 (enExample)
HU (1) HU229664B1 (enExample)
IL (3) IL143905A0 (enExample)
MX (1) MXPA01006427A (enExample)
NO (1) NO330800B1 (enExample)
NZ (1) NZ512574A (enExample)
OA (1) OA11736A (enExample)
PL (3) PL205041B1 (enExample)
PT (3) PT1141306E (enExample)
TR (2) TR200200633T2 (enExample)
UY (1) UY25877A1 (enExample)
WO (1) WO2000039299A2 (enExample)
ZA (1) ZA200105114B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757697A3 (en) 1998-02-20 2007-05-30 ID Biomedical Corporation Group B streptococcus antigens
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
WO2000037105A2 (en) * 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
DK1141306T3 (da) * 1998-12-23 2008-08-18 Id Biomedical Corp Streptococcus-antigener
ATE412673T1 (de) 2000-06-12 2008-11-15 Univ Saskatchewan Chimäres gapc protein aus streptococcus und dessen verwendung zur impfung und diagnostik
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
EP1303612A2 (en) * 2000-06-20 2003-04-23 Shire Biochem Inc. Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
AU2002242549A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
JP4374245B2 (ja) * 2001-07-06 2009-12-02 アイディー バイオメディカル コーポレイション グループb連鎖球菌の抗原及び対応するdna断片
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
WO2003054007A2 (en) * 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
PT1601770E (pt) * 2003-03-04 2009-12-07 Intercell Ag Antigénios de streptococcus pyogenes
AU2004230244B2 (en) 2003-04-15 2011-09-22 Intercell Ag S. pneumoniae antigens
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20090010959A1 (en) 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
HRP20151122T1 (hr) 2007-06-26 2015-11-20 Glaxosmithkline Biologicals S.A. Cjepivo koje sadrži konjugate polisaharida iz kapsule bakterije streptococcus pneumoniae
WO2009012588A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
CA2720961A1 (en) 2008-04-16 2009-10-22 William Ripley Ballou, Jr. Streptococcus pneumonia vaccine
US8962026B2 (en) 2008-09-26 2015-02-24 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
NZ620441A (en) 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドSanofi Pasteur Limited 肺炎球菌に対する免疫用組成物
EP2665490B1 (en) * 2011-01-20 2020-03-04 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
EA201391456A1 (ru) 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
US10161940B2 (en) * 2012-01-05 2018-12-25 Deutsches Krebsforschungszentrum Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
US20160324949A1 (en) 2014-01-21 2016-11-10 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
SI3096783T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3104886B1 (en) 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
MX395525B (es) 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
AU2016295566B2 (en) 2015-07-21 2019-06-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CA3148824A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
KR20220144393A (ko) 2020-02-21 2022-10-26 화이자 인코포레이티드 당류의 정제
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
US20230383324A1 (en) 2020-10-22 2023-11-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
AU2021368151B2 (en) 2020-10-27 2024-09-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4346892A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2025508749A (ja) 2022-01-13 2025-04-10 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
US20250312433A1 (en) 2022-05-11 2025-10-09 Pfizer Inc. Process for Producing of Vaccine Formulations With Preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250169621A (ko) 2023-04-14 2025-12-03 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121263203A (zh) 2023-05-19 2026-01-02 葛兰素史克生物有限公司 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
EP0656014B1 (en) * 1993-03-19 2003-05-14 LINDAHL, Gunnar Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
EP0832238A1 (en) * 1995-06-07 1998-04-01 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
DK0942983T4 (en) * 1996-10-31 2014-12-01 Human Genome Sciences Inc Streptococcus pneumoniae antigens and vaccines
CN1291233A (zh) * 1997-09-24 2001-04-11 美国明尼苏达州大学 来自肺炎链球菌之人类补体c3降解蛋白酶
CA2328399A1 (en) * 1998-04-23 1999-10-28 University Of Alabama At Birmingham Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor
JP2002531055A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌のタンパク質及び核酸分子
JP2002521058A (ja) * 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
CN1352691A (zh) * 1998-09-24 2002-06-05 美国明尼苏达州大学 来自肺炎链球菌的人补体c3降解性多肽
WO2000037105A2 (en) * 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
DK1141306T3 (da) * 1998-12-23 2008-08-18 Id Biomedical Corp Streptococcus-antigener

Also Published As

Publication number Publication date
PL205041B1 (pl) 2010-03-31
CN1332803A (zh) 2002-01-23
PT2261358E (pt) 2014-07-30
KR100802198B1 (ko) 2008-02-11
HK1118575A1 (en) 2009-02-13
ES2400280T3 (es) 2013-04-08
KR20080036666A (ko) 2008-04-28
PT1950302E (pt) 2013-01-16
PL206576B1 (pl) 2010-08-31
PL349777A1 (en) 2002-09-09
WO2000039299A2 (en) 2000-07-06
ES2480417T3 (es) 2014-07-28
AR029322A1 (es) 2003-06-25
DK2261358T3 (da) 2014-07-28
ES2306528T3 (es) 2008-11-01
UY25877A1 (es) 2000-08-21
DK1950302T3 (da) 2013-01-14
CN100398653C (zh) 2008-07-02
NZ512574A (en) 2004-03-26
HU229664B1 (en) 2014-04-28
IL194230A (en) 2013-12-31
ATE394489T1 (de) 2008-05-15
HUP0104774A2 (hu) 2002-04-29
CN101134775A (zh) 2008-03-05
CZ302790B6 (cs) 2011-11-09
BR9916477A (pt) 2004-06-22
PT1141306E (pt) 2008-07-30
OA11736A (en) 2005-06-12
CY1114722T1 (el) 2016-10-05
KR101170203B1 (ko) 2012-07-31
EP1141306A2 (en) 2001-10-10
NO20013045D0 (no) 2001-06-19
KR20100063814A (ko) 2010-06-11
EP2261358A2 (en) 2010-12-15
JP2010142246A (ja) 2010-07-01
KR101078919B1 (ko) 2011-11-01
ZA200105114B (en) 2002-11-21
JP4761623B2 (ja) 2011-08-31
HUP0104774A3 (en) 2007-10-29
CZ20012161A3 (cs) 2001-10-17
DE69938670D1 (de) 2008-06-19
NO20013045L (no) 2001-08-20
CA2356836C (en) 2011-09-13
KR20060134227A (ko) 2006-12-27
AU1764900A (en) 2000-07-31
KR100891398B1 (ko) 2009-04-02
CZ303675B6 (cs) 2013-02-27
TR200102497T2 (tr) 2002-01-21
WO2000039299A3 (en) 2000-11-02
CA2356836A1 (en) 2000-07-06
MXPA01006427A (es) 2002-06-04
IL143905A (en) 2011-05-31
CL2009002037A1 (es) 2010-06-25
IL143905A0 (en) 2002-04-21
PL204073B1 (pl) 2009-12-31
CN1191362C (zh) 2005-03-02
EP2261358B1 (en) 2014-05-14
EP2261358A3 (en) 2011-02-23
JP2002533123A (ja) 2002-10-08
AP2001002199A0 (en) 2001-09-30
IL194230A0 (en) 2011-08-01
EP1141306B1 (en) 2008-05-07
DK1141306T3 (da) 2008-08-18
KR20010104693A (ko) 2001-11-26
CY1115340T1 (el) 2017-01-04
CN1654657A (zh) 2005-08-17
TR200200633T2 (tr) 2002-06-21
EA007409B1 (ru) 2006-10-27
EA200100565A1 (ru) 2002-04-25
JP5039802B2 (ja) 2012-10-03
NO330800B1 (no) 2011-07-18

Similar Documents

Publication Publication Date Title
CY1114722T1 (el) Αντιγονα στρεπτοκοκκου
EA200201280A1 (ru) Стрептококковые антигены
AP2000001886A0 (en) Group B streptococcus antigens.
DE69935986D1 (de) Streptococcus pneumoniae proteine und nukleinsäuren
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
PT1203817E (pt) Compostos e metodos para imunoterapia e le diagnostic de tuberculose
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
CY1107636T1 (el) Πρωτεϊνες moraxella catarrhalis
DK0491713T3 (da) Rubella El-peptider og C-peptider
MX9301736A (es) Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
BR9808251B1 (pt) vacina, e, uso de uma proteìna isolada ou recombinante ou fragmento antigênico da mesma.
AR020852A1 (es) Antigenos de vacuna de leptospira para la prevencion de leptospirosis
CY1108761T1 (el) Απενεργοποιημενες κυτοκινες για ανοσοποιηση
CY1108412T1 (el) Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis
ATE345812T1 (de) Antigen-mimotope und vakzine gegen krebserkrankungen
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους
EP1950302A3 (en) Streptococcus antigens
CY1116907T1 (el) Ανασυνδυασμενα εμβολια κατα κωπηποδων καλιγιδων (θαλασσιων ψειρων) και αλληλουχιες αντιγονων αυτων